The Federal Trade Commission will launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers to provide information and records regarding their business practices within 90 days, the agency announced today. FTC said the inquiry will scrutinize the impact of vertically integrated PBMs on the access and affordability of prescription drugs. 

AHA last month urged the FTC to investigate certain practices by health plans and pharmacy benefit manager, commonly referred to as “white bagging,” which disallow health care providers from procuring and managing the drugs they administer to patients.

“As large health plans engage in broad vertical integration efforts, including the acquisition of PBMs and specialty pharmacies, the practice of mandated white bagging has increased dramatically,” forcing hospitals and health systems “to navigate substantial supply chain and logistical challenges in order to continue to provide safe and effective care to the patients they treat,” AHA told the agency. 

Related News Articles

Headline
Susan Doherty, AHA’s vice president of field engagement, and Rebecca Chickey, AHA’s senior director of behavioral health services, write on the unique ways…
Blog
This year, the Centers for Disease Control and Prevention reported that over 49,000 people died by suicide in 2023, the latest year for which data was…
Headline
The Food and Drug Administration recently disclosed dozens of warning letters sent to drug companies that accuse them of using misleading or deceptive…
Headline
Corey Feist, CEO and co-founder of the Dr. Lorna Breen Heroes Foundation, and Tiffany Lyttle, R.N., director of cultural integration at Centra Health, discuss…
Headline
A Gallup report published Sept. 9 found that nearly 48 million Americans currently have or are being treated for depression. The total, which equals 18.3% of…
Headline
President Trump Sept. 10 signed a memorandum directing the Department of Health and Human Services and Food and Drug Administration to require drug companies…